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436Quality-of-life scores in neurogenic thoracic outlet
syndrome patients undergoing ﬁrst rib resection
and scalenectomy
Danielle H. Rochlin, BA,a Marta M. Gilson, PhD,b Kendall C. Likes,a Emma Graf, BA,a Nancy Ford,a
Paul J. Christo, MD, MBA,c and Julie A. Freischlag, MD,a Baltimore, Md
Objective: First rib resection and scalenectomy (FRRS) has been shown to improve short-term quality of life (QOL) in the
treatment of neurogenic thoracic outlet syndrome (NTOS). Long-term beneﬁts are not well studied but are believed to
decrease over time. Our objective was to evaluate long-term NTOS outcomes using validated QOL instruments.
Methods: We identiﬁed 162 NTOS patients aged $18 years treated by FRRS from 2003 to 2010 after they had not
responded to conservative management. The patients were mailed three surveys to assess QOL (Short-Form 12 [SF-12],
Brief Pain Inventory [BPI], and Cervical Brachial Symptom Questionnaire [CBSQ]), with ﬁve total outcomes measures
including the SF-12 Physical Component Score (PCS), SF-12 Mental Component Score (MCS), BPI severity, BPI
interference, and CBSQ score. Demographic and clinical data were extracted from patient records. Each FRRS was
categorized based on postoperative clinical assessment as successful, failed, or leading to recurrent symptoms.
Results: Survey yield was 53.7% (n[ 87) with mean follow-up of 44.7 months (range, 12.4-91.9 months). There was no
signiﬁcant difference in QOL scores associated with long-term compared with short-term follow-up. Signiﬁcantly poorer
scores on all instruments were associated with comorbid chronic pain syndromes, opioid use, and unfavorable clinical
assessment (P < .05). Signiﬁcantly poorer scores on select instruments were associated with smoking (BPI both; P < .02),
age $40 years (SF-12 PCS, BPI interference, CBSQ; P < .03), neck and/or shoulder disease (SF-12 both, BPI both; P <
.01), postoperative injections (BPI both, CBSQ; P < .05), and complications (SF-12 PCS, CBSQ; P < .05). A positive
preoperative scalene block was not signiﬁcantly associated with long-term QOL scores.
Conclusions: The QOL after FRRS shows no signiﬁcant difference with longer follow-up. Clinical assessment reﬂects
patient-reported outcomes and can gauge postoperative improvement. Patient factors, particularly comorbidities and
opioid use, are more predictive of long-term QOL than is preoperative scalene block and should also be considered when
selecting patients for surgical intervention. (J Vasc Surg 2013;57:436-43.)Neurogenic thoracic outlet syndrome (NTOS) is
a collection of symptoms caused by compression of roots
of the brachial plexus during passage through the thoracic
outlet. Patients may present with pain, weakness, or pares-
thesia in the affected upper extremity, in addition to cold
intolerance or occipital headaches.1 Such symptoms lead
to signiﬁcant debilitation. Patients with NTOS experience
a level of impairment similar to that of patients withthe Division of Vascular Surgery and Endovascular Therapy,a the
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://dx.doi.org/10.1016/j.jvs.2012.08.112chronic heart failure, with a mean Short-Form 12
(SF-12) Physical Component Score (PCS) and Mental
Component Score (MCS) below the population norm.2
Management often begins with physical therapy and life-
style modiﬁcation and may involve computed tomography
(CT)-guided botulinum toxin A (Botox) injections into the
anterior scalene muscle for symptom relief lasting up to 3
months.3 Approximately 30% to 40% of NTOS patients
will not respond to conservative therapy and will present
as candidates for surgical decompression by ﬁrst rib resec-
tion and scalenectomy (FRRS).1
Surgical intervention for NTOS remains controversial
due to uncertainties in diagnosis and treatment. The diag-
nosis of NTOS has historically lacked objective criteria,
relying heavily on patient complaints and physical examina-
tion ﬁndings. Somatosensory-evoked potentials, nerve
conduction studies, electromyography, and imaging studies
can exclude alternative causes of symptoms but have
limited speciﬁcity for the diagnosis of NTOS.4,5 In terms
of treatment, reports of insigniﬁcant differences in
outcomes between patients treated conservatively and
those treated surgically have led to questions about the
need for surgical intervention.6,7 In addition, although
short-term surgical outcomes appear favorable, long-term
outcomes remain uncertain. Chang et al2 demonstrated
PCS and MCS improvements of 0.24 points (P < .001)
and 0.15 points (P ¼ .01) per month, respectively, during
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to quality-of-life (QOL) improvements among NTOS
patients in the short term. However, available long-term
data show a decline in symptom resolution from 87%
initially to 38% at 36 postoperative months, suggesting
that surgical beneﬁts may decrease over time.8 Other
long-term studies demonstrate more encouraging out-
comes but are limited by small sample size and/or subjec-
tive methods of postoperative evaluation.9-12
The objective of this study was to assess long-term
outcomes following FRRS for treatment of NTOS. In
addition to earlier studies evaluating postoperative QOL
in the short term, we previously examined factors predis-
posing to unresolved, recurrent, and/or contralateral
symptoms postoperatively.2,13 However, this study is the
ﬁrst to examine long-term QOL outcomes in a large
cohort of patients using validated QOL instruments.
METHODS
After Institutional Review Board approval for the study
was obtained, 162 NTOS patients presenting to Johns
Hopkins from 2003 to 2010 were identiﬁed by review of
an internal database, prospectively maintained by the Johns
Hopkins Division of Vascular Surgery and Endovascular
Therapy. All patients had undergone transaxillary FRRS
after they had not responded to conservative management
with physical therapy. Selection criteria included age $18
years, >1 year of postoperative follow-up, and lack of prior
TOS-related surgical intervention on the affected side.
Data on patient demographics and clinical outcomes
were abstracted from the database and from patients’ elec-
tronic medical records. Variables collected included gender,
age, length of symptoms, NTOS etiology, smoking status,
comorbid conditions, preoperative and postoperative inter-
ventions, and complications. Theoperating surgeon assessed
the efﬁcacy of each FRRS procedure during postoperative
clinic visits and categorized outcomes based on the pattern
of symptom resolution. Outcomes were considered success-
ful if FRRS led to relief of TOS-related symptoms in accor-
dance with best clinical practice. Failed outcomes were
characterized by a persistence of TOS-related symptoms at
the end of the follow-up period. Recurrent symptoms were
deﬁned as those that reappeared after initial resolution. For
patients who underwent bilateral FRRS procedures due to
dual-sided NTOS symptoms, demographic data at the time
of the ﬁrst FRRSwere used for analysis. The clinical outcome
of each side was assessed independently.
Patients completed three QOL instruments (SF-12
version 1, Brief Pain Inventory [BPI] short form, and
Cervical Brachial Symptom Questionnaire [CBSQ]) via
mail, with the exception of a limited number of patients
who requested phone or clinic administration. Patients
who did not return the survey were sent a second mailing
and encouraged via telephone to participate. The SF-12
is a general health survey that assesses functional outcomes
and well-being through measurement of eight health
domains (physical functioning, role-physical, bodily pain,
general health, vitality, social functioning, role-emotional,and mental health).14 SF-12 survey data were used to
compute PCS and MCS using QualityMetric Health
Outcomes Scoring Software 4.0 (QualityMetric Inc,
Lincoln, RI). Scores were normalized to the United States
general population (mean [standard deviation] ¼ 50 [10])
and reported on a scale from 0 to 100, with lower scores
being more unfavorable. The BPI characterizes acute or
chronic pain based on pain severity and interference scores
calculated by the arithmetic mean of four severity and seven
interference items, respectively, both reported on a scale
from 0 to 10, with higher scores being more unfavorable.15
Additional BPI assessment areas include pain location,
measured by body diagram, and pain medication usage
and associated relief. The CBSQ is the most speciﬁc for
neck, arm, and shoulder impairment. It quantiﬁes the
extent of TOS-related symptoms (pain, fatigue, swelling,
paresthesia, and numbness) in the upper extremity with
certain activities. Jordan et al16 developed the CBSQ as
a tool to differentiate NTOS from other pain syndromes
affecting the cervical area, with higher scores being more
unfavorable and reﬂective of widespread hypersensitive
states such as ﬁbromyalgia. CBSQ analysis involved addi-
tion of line item scores to yield an overall score on a scale
from 0 to 120 and localization of pain and sensory distur-
bances by body diagram.
Linear regression was used to assess the cross-sectional
relationship between survey score and postoperative
follow-up time, deﬁned as the months between surgery
(ﬁrst FRRS for bilateral patients) and the date of survey
completion. Analysis of variance, c2 test, and Fisher exact
test evaluated associations of patient variables and clinical
assessment with survey score, in addition to potential
survey response bias. Pearson correlation was used to test
associations among the different survey instruments and
scales. Correlation coefﬁcients were categorized as weak
(.00-.39), moderate (.40-.69), or strong (.70-1.00). All
statistical analyses were conducted using SAS software,
version 9.3 (SAS Institute Inc, Cary, NC) at the patient
level. Statistical signiﬁcance was deﬁned as P < .05.
RESULTS
Respondent characteristics. Characteristics of the
study population are summarized in Table I. A total of
87 of 162 patients completed the questionnaires, yielding
a 53.7% response rate. Nineteen patients were lost to
follow-up. Mean follow-up time was 44.7 months (range,
12.4-91.9 months). Respondents had a mean age at the
time of surgery of 41.0 years (range, 21-63 years) and
included 72 females (82.8%) and 15 males (17.2%).
Symptoms had been present for a mean of 57.1 months
(range, 1-516 months; n ¼ 86) and occurred secondary to
trauma in 40 respondents (46.0%) and chronic repetitive
motion injury in 47 respondents (54.0%). Eleven respon-
dents (12.6%) were active smokers. Comorbid conditions
included chronic pain (eg, complex regional pain
syndrome, ﬁbromyalgia, and rheumatoid arthritis) in 21
respondents (24.1%), neck and/or shoulder disease (eg,
disc degeneration, shoulder tendonitis or bursitis, and
Table I. Sample characteristics (n ¼ 87)
Mean length of follow-up (range),
months
44.7 (12.4-91.9)
Mean length of symptoms (range),
months (n ¼ 86)
57.1 (1-516)
Mean age (range), years 41.0 (21-63)
Active smokers 11 (12.6%)
Bilateral patients 17 (19.5%)
Gender
Male 15 (17.2%)
Female 72 (82.8%)
Race
Caucasian 78 (89.7%)
African American 3 (3.4%)
Other/unknown 6 (6.9%)
Cause
Trauma 40 (46.0%)
Repetitive motion 47 (54.0%)
Comorbid conditions
Chronic pain syndrome 21 (24.1%)
Neck/shoulder disease 31 (35.6%)
General comorbidity 48 (55.2%)
Opioids
Preoperative use 25 (28.7%)
Postoperative use 18 (20.7%)
Preoperative interventions
TOS physical therapy 66 (75.9%)
Scalene block 63 (72.4%)
Miscellaneous injection(s) 33 (37.9%)
Botox injection(s) 24 (27.6%)
Non-TOS surgery 26 (29.9%)
Postoperative interventions
Miscellaneous injection(s) 7 (8.1%)
Botox injection(s) 9 (10.3%)
Non-TOS surgery 12 (13.8%)
Complications
Pain 26 (29.9%)
Swelling 5 (5.8%)
Scar tissue 18 (20.7%)
Pneumothorax 19 (21.8%)
Reinjury 7 (8.1%)
Mean QOL survey scores
SF-12 PCS 44.34  11.32
SF-12 MCS 51.30  11.02
BPI severity 3.21  2.54
BPI interference 2.75  2.74
CBSQ 36.15  31.12
BPI, Brief Pain Inventory; CBSQ , Cervical Brachial Symptom Question-
naire; MCS, Mental Component Score; PCS, Physical Component Score;
QOL, quality of life; SF-12, Short-Form 12; TOS, thoracic outlet syndrome.
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disease, and injury. In general, 48 respondents (55.2%)
had $1 comorbid conditions. All patients received but
did not respond to preoperative physical therapy. Other pre-
operative interventions included additional TOS-directed
physical therapy (n ¼ 66 [75.9%]), anesthetic and/or
steroid injections (n ¼ 33 [37.9%]), and previous surgeries
other than FRRS (n ¼ 26 [29.9%]) in regions of the neck
and/or upper extremity, CT-guided Botox injections into
the anterior scalene muscle (n ¼ 24 [27.6%]), and opioid
use (n ¼ 25 [28.7%]). Anterior scalene block with bupiva-
caine was used to assess surgical candidacy in 63 cases
(72.4%), with 92.1% of patients reporting symptom relief.
Beyond physical therapy, postoperative management in-cluded anesthetic and/or steroid injections (n ¼ 7 [8.1%]),
CT-guided Botox injections (n ¼ 9 [10.3%]), non-TOS
surgery (n ¼ 12 [13.8%]), and opioid use (n ¼ 18
[20.7%]). Postoperative complications included pain (n ¼
26 [29.9%]), swelling (n ¼ 5 [5.8%]), pneumothorax
(n ¼ 19 [21.8%]), reinjury (n ¼ 7 [8.1%]), and excessive
scar tissue formation, diagnosed clinically by palpation in
the supraclavicular fossa and patient report of discomfort
during use of the operated arm (n ¼ 18 [20.7%]). Preop-
erative and postoperative anesthetic and steroid injections
involved procedures such as epidural and trigger point
injections in TOS-related regions. Seventeen respondents
(19.5%) underwent bilateral FRRS.
Most demographic and clinical characteristics did not
differ signiﬁcantly between respondents and nonrespon-
dents. Notably, there was a greater percentage of female
respondents compared with nonrespondents (82.8% vs
66.7%; P ¼ .028). In addition, a greater proportion of
respondents compared with nonrespondents underwent
bilateral FRRS (19.5% vs 5.3%; P ¼ .009).
Quality of life at follow-up intervals. Mean (stan-
dard deviation) survey scores over the follow-up interval
were as follows: 44.34 (11.32) for PCS, 51.30 (11.02) for
MCS, 3.21 (2.54) for BPI severity, 2.75 (2.74) for BPI
interference, and 36.15 (31.12) for CBSQ. Mean PCS
was slightly lower (worse QOL) than the general pop-
ulation norm of 50, whereas mean MCS was slightly
higher. Both BPI and CBSQ scores were low on the
respective scales from 0 to 10 and 0 to 120, indicating
better QOL.
The QOL after FRRS showed no signiﬁcant difference
with longer follow-up on any of the survey instruments.
Linear regression of each of the ﬁve survey measures with
cross-sectional follow-up month is illustrated in Fig 1.
The SF-12 PCS and MCS linear regression coefﬁcients
indicate worse QOL associated with longer follow-up but
were not statistically signiﬁcant, with values of e.042
(P ¼ .461) and e.060 (P ¼ .281), respectively. Linear
regression coefﬁcients were similarly associated but not
signiﬁcantly for BPI severity (.017; P ¼ .180), BPI interfer-
ence (.022; P ¼ .106), and CBSQ (.137; P ¼ .385).
Survey correlation. Pearson correlation coefﬁcients
for pairwise comparisons of the ﬁve survey measures are
given in Table II. Note that SF-12 (PCS, MCS) has
opposite directionality compared with BPI (severity,
interference) and CBSQ; higher scores are favorable for SF-
12 and unfavorable for BPI and CBSQ. The PCS was
strongly associated with BPI interference (e.730) and
CBSQ (e.698) and was moderately associated with BPI
severity (e.680); PCS and MCS were not signiﬁcantly
associated. The MCS was moderately associated with BPI
severity (e.432) and interference (e.622) but was not
associated with CBSQ. The BPI severity and interference
were strongly associated (.843), and both were moderately
associated with CBSQ (.679 and .633, respectively). For all
signiﬁcant associations, P < .001.
Clinical assessment. Based on postoperative assess-
ment of symptoms during clinic visits, 63 respondents
Fig 1. Quality-of-life (QOL) outcomes at follow-up intervals. Linear regression of survey score and cross-sectional
follow-up month (FU Month) is shown for the Short-Form 12 (SF-12) (A) Physical Component Score (PCS) and
(B) Mental Component Score (MCS), Brief Pain Inventory (BPI) (C) severity and (D) interference scales, and (E)
Cervical Brachial Symptom Questionnaire (CBSQ).
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(9.2%) had failed outcomes. Ten respondents (11.5%)
developed recurrent symptoms in the postoperative period.
Five respondents (5.7%) who underwent bilateral FRRS had
mixed outcomes (eg, a success on one side and a failure or
recurrent symptoms on the second side). The clinicaloutcome of one respondent was unknown due to insufﬁ-
cient follow-up. Fig 2 shows a comparison of survey score
by clinical assessment, excluding bilateral respondents with
mixed clinical outcomes (n ¼ 5) and the single respondent
with an unknown clinical outcome. Survey score differed
signiﬁcantly among patients with different clinical outcomes
Table II. Pearson correlation coefﬁcients for comparison of survey measures
MCS BPI severity BPI interference CBSQ
PCS .168 (NS) .680 (P < .001) e.730 (P < .001) .698 (P < .001)
MCS d .432 (P < .001) .622 (P < .001) .178 (NS)
BPI severity d d .843 (P < .001) .679 (P < .001)
BPI interference d d d .633 (P < .001)
BPI, Brief Pain Inventory; CBSQ, Cervical Brachial Symptom Questionnaire; MCS, Mental Component Score; NS, not signiﬁcant (P $ .05); PCS, Physical
Component Score.
Fig 2. Association of clinical assessment with survey score. Mean survey scores over the follow-up interval are plotted
along with standard error (bars). Categorization by clinical assessment is shown for the (A) Short-Form 12 (SF-12)
Physical Component Score (PCS) and Mental Component Score (MCS) and Cervical Brachial Symptom Questionnaire
(CBSQ) and the (B) Brief Pain Inventory (BPI) pain severity and interference scales. Bilateral patients with mixed
clinical assessments (n ¼ 5) or unknown assessment (n ¼ 1) were excluded.
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were associated with an assessment of success and poorer
scores were associated with an assessment of failure. With
the exception of MCS, recurrent symptoms were associated
with an intermediate score on all survey measures.
Residual symptom distribution. The distribution of
postoperative pain and sensory disturbance, measured by
BPI and CBSQ body diagrams, is shown in Fig 3.
Respondents most frequently indicated residual pain in the
shoulder (BPI, 50.6%; CBSQ, 37.9%), neck (BPI, 36.8%;
CBSQ, 28.7%), and upper arm (BPI, 32.2%; CBSQ,
28.7%). Pain in each of these regions was associated with
signiﬁcantly worse scores on respective BPI (severity and
interference; P < .03) and CBSQ (P < .002) instruments.
The most frequent sites of residual sensory disturbance
were the ﬁngers (CBSQ, 59.8%), hand (CBSQ, 43.7%),
and lower arm (CBSQ, 31.0%). With the exception of the
ﬁngers (P ¼ .103), sensory disturbance in these regions was
also signiﬁcantly associated with worse CBSQ scores (P <
.004). Residual symptoms in non-TOS regions or infre-
quent areas yielded the most severe QOL impairment.
When analyzed by symptom distribution, the worst mean
scores on the BPI survey were found among respondents
reporting pain on the BPI in the head (BPI severity, 5.63;
BPI interference, 5.89) and ﬁngers (BPI severity, 4.92; BPI
interference, 5.33). Respondents with the poorest scores
on the CBSQ had pain in non-TOS regions (CBSQ,
66.29) and ﬁngers (CBSQ, 62.00) and sensory disturbance
in non-TOS regions (CBSQ, 82.25) and the shoulder(CBSQ, 71.88). Some respondents also reported newly
developed contralateral symptoms; 31.4% (BPI) and 18.6%
(CBSQ) of respondents who had not formerly undergone
bilateral FRRS reported contralateral pain symptoms,
whereas 14.3% of respondents indicated contralateral
sensory disturbance.
Predictors of worse scores. Demographic and clinical
patient variables associatedwithworseQOLsurvey scores are
given in Table III. Factors associated with signiﬁcantly worse
scores on all ﬁve survey instruments include chronic pain
syndromes (P < .03), general comorbidity (P < .009), and
preoperative (P < .04) and postoperative (P < .001) opioid
use.Variables predictive of signiﬁcantlyworse scores on select
survey instruments include active smoking status (BPI
severity, P ¼ .002; BPI interference, P ¼ .013), age $40
years (PCS,P¼ .002; BPI interference,P¼ .009;CBSQ,P¼
.027), neck and/or shoulder disease (PCS, P ¼ .005; MCS,
P¼ .003;BPI severity,P¼ .006,BPI interference,P¼ .001),
postoperative CT-guided Botox injections (BPI severity, P¼
.014; BPI interference, P ¼ .025) and anesthetic and/or
steroid injections (BPI severity, P ¼ .001; BPI interference,
P¼ .045; CBSQ, P ¼ .006), and complications that include
pain (PCS, P¼ .005) and scar tissue (MCS, P¼ .004). Relief
from preoperative scalene block with bupivacaine was not
predictive of score on any instrument.
DISCUSSION
A lack of robust long-term outcomes data continues to
challenge the acceptance of surgical intervention as
Fig 3. Distribution of postoperative pain and sensory disturbance. A, Brief Pain Inventory (BPI) body diagram
measured residual pain. Cervical Brachial Symptom Questionnaire (CBSQ) body diagram measured both (B) pain and
(C) sensory disturbance.
Table III. Mean survey scores and P values for variables predictive of worse scoresa
PCS MCS BPI severity BPI interference CBSQ
Patient characteristics
Active smoker 41.41 (NS) 45.34 (P ¼ .054) 5.36 (P ¼ .002) 4.64 (P ¼ .013) 52.91 (P ¼ .056)
Age $40 years 40.83 (P ¼ .002) 49.96 (NS) 3.62 (NS) 3.47 (P ¼ .009) 43.09 (P ¼ .027)
Comorbid conditions
Chronic pain syndrome 35.13 (P < .001) 46.27 (P ¼ .015) 4.29 (P ¼ .025) 4.77 (P < .001) 49.43 (P ¼ .024)
Neck/shoulder disease 39.80 (P ¼ .005) 46.67 (P ¼ .003) 4.21 (P ¼ .006) 4.09 (P ¼ .001) 43.94 (NS)
General comorbidity 39.32 (P < .001) 47.93 (P ¼ .001) 4.16 (P < .001) 3.94 (P < .001) 44.08 (P ¼ .008)
Opioids
Preoperative use 39.71 (P ¼ .014) 43.19 (P < .001) 4.45 (P ¼ .004) 4.59 (P < .001) 46.96 (P ¼ .039)
Postoperative use 33.11 (P < .001) 39.97 (P < .001) 5.78 (P < .001) 6.12 (P < .001) 65.22 (P < .001)
Postoperative injections
Miscellaneous injection(s) 41.85 (NS) 43.94 (NS) 6.34 (P ¼ .001) 4.73 (P ¼ .045) 66.71 (P ¼ .006)
Botox injection(s) 43.85 (NS) 47.65 (NS) 4.29 (P ¼ .014) 3.81 (P ¼ .025) 41.42 (NS)
Complications
Pain 39.22 (P ¼ .005) 48.61 (NS) 3.81 (NS) 3.51 (NS) 45.69 (NS)
Scar tissue 41.99 (NS) 57.81 (P ¼ .004) 2.97 (NS) 2.06 (NS) 42.39 (NS)
Any complication 41.55 (P ¼ .014) 51.17 (NS) 3.43 (NS) 3.02 (NS) 42.61 (P ¼ .040)
BPI, Brief Pain Inventory; CBSQ , Cervical Brachial Symptom Questionnaire; MCS, Mental Component Score; NS, not signiﬁcant (P $ .05); PCS, Physical
Component Score.
aCharacteristics for bilateral patients are based on ﬁrst surgery
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previous studies with insufﬁcient follow-up duration or
small sample size, our study evaluated the long-term
outcomes of 87 NTOS patients with a mean follow-up
time of 44.7 months (range, 12.4-91.9 months). Our anal-
ysis illustrates that QOL after surgical intervention for
NTOS refractory to conservative management shows no
signiﬁcant linear association with longer follow-up andyields mean survey scores that indicate encouraging QOL
levels. Collectively, these ﬁndings contradict prior evidence
that symptom relief declines over time and suggest that
FRRS can achieve effective long-term results in appropri-
ately selected NTOS patients.
Our use of validated QOL instruments contrasts with
the inconsistent and subjective assessment measures used
in previous studies. The BPI and CBSQ scales and
JOURNAL OF VASCULAR SURGERY
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associated with PCS, a measure that previously has been
shown to track postoperative improvement in NTOS.2
This ﬁnding supports the use of these and other validated
survey instruments in evaluating NTOS surgical outcomes,
although few studies have used comparable standardized
measures.2,7,17 Many outcomes studies use custom nonva-
lidated surveys to assess patient-reported QOL, where the
content of such surveys may include qualitative patient
assessment of symptom relief (excellent, good, fair, or
poor), satisfaction with outcome, medication usage, and/
or ability to return to preoperative work and leisure activi-
ties.6,8-12,18,19 As noted in a review of TOS outcomes liter-
ature, such differences in measurement and deﬁnitions of
surgical success have led to variability in reported rates of
postoperative improvement, with estimates ranging from
43% to 96%.19 This inconsistency reﬂects the need for
greater standardization and objectivity in evaluation of
postsurgical improvement.
Without diminishing the need for greater standardiza-
tion, our study does support the ability of the surgeon to
adequately gauge postoperative QOL in NTOS patients
during clinical encounters. The association of more favor-
able survey scores with clinical assessments of success and
lower scores with clinical failures illustrates the ability of
the skilled clinician to identify and appreciate the degree
of impairment associated with NTOS symptoms. The rela-
tively high mean MCS for respondents with recurrent
symptoms may reﬂect a unique psychological approach to
recurrent symptoms or the generally weaker association
between MCS and other survey measures.
Analysis of BPI and CBSQ body diagrams yielded
a deﬁnable pattern of residual symptoms. The most
frequent sites of residual pain were the shoulder, neck,
and upper arm, whereas sensory disturbance was most
frequently localized to the ﬁngers, hand, and lower arm.
These ﬁndings are expected given the pathophysiology of
NTOS, where muscular ﬁbrosis or spasm may lead to
pain in the shoulder region, and impingement of C8-
T1 nerve roots of the brachial plexus may lead to
weakness and paresthesia. Interestingly, respondents with
uncommon patterns of residual symptoms (eg, pain in
the ﬁngers or sensory disturbance in the neck) or symptoms
in regions unrelated to TOS (eg, legs or lower back) indi-
cated greater QOL impairment on average. Jordan et al16
similarly reported that patients who responded poorly to
treatment indicated sensory and motor disturbance beyond
the hand and forearm. This pattern may be evidence of the
greater morbidity associated with widespread symptoms, or
it may reﬂect an underlying relationship between chronic
pain syndromes and poor QOL.
Comorbid conditions associated with chronic pain were
predictive of poorer QOL outcomes in our analysis, as were
neck and/or shoulder disease and a general comorbidity
category including other systemic disease and injury. These
predictors may be related to diagnostic confusion. Symp-
toms of ﬁbromyalgia, rheumatoid arthritis, peripheral nerve
compression, injury or inﬂammation of shoulder muscles,and cervical disc degeneration may resemble NTOS but
will not be relieved by surgical decompression.1 Patients
may also present with somatoform disorders or other
psychological disturbance concomitant with years of debili-
tating symptoms.20 Prior studies of NTOS postoperative
outcomes have similarly noted the association between
comorbid pain syndromes and diffuse neurologic distur-
bance and/or poor recovery, supporting the importance of
differentiating true cases of NTOS from clinical mimics by
paying close attention to the pattern of presenting symp-
toms.9,16 For instance, although NTOS patients typically
have numbness in the ulnar nerve distribution or entire
arm, sensory disturbance is often limited to the median
and radial nerve distributions in carpal tunnel syndrome
and cervical disc disease, respectively.5 In addition to comor-
bid conditions, factors associated with poorer scores in our
analysis include active smoking status, age$40 years, preop-
erative and postoperative opioid use, postoperative Botox
and anesthetic and/or steroid injections in TOS-related
regions, and complications such as pain and scar tissue.
These ﬁndings, with outcome based on patient-reported
QOL, support the results of our previous study showing
that such factors are associated with poor outcome as deter-
mined by clinician assessment.13
Anterior scalene block may provide diagnostic support
for NTOS, although prognostic beneﬁts proven in the short
term do not appear to translate to the longer-term period of
follow-up in our study. Relief of symptoms after ultrasound,
electromyogram, or CT-guided injection of bupivacaine
or lidocaine, which relaxes the anterior scalene muscle
and decompresses the region, suggests that neurovascular
compression secondary to muscle spasm or ﬁbrosis is
the cause of symptoms.21-23 A positive response to scalene
block has been shown to correlate with favorable surgical
outcomes within 1 postoperative year.22,23 However, in
our analysis, relief from preoperative scalene block with
bupivacaine was not signiﬁcantly associated with survey
score on any instrument, suggesting that this test is not
entirely predictive of long-term QOL outcomes. Instead,
long-term performance may be more reﬂective of patient
factors because behavioral and clinical traits may dominate
the patient’s continued QOL after the immediate physical
relief postoperatively.
Although this study demonstrated that postoperative
QOL scores at longer follow-up intervals were not signiﬁ-
cantly different than at shorter follow-up intervals, it was
unable to demonstrate any pattern over time due to the
cross-sectional design. Longitudinal QOL data would
allow for improved patient follow-up and assessment and
is the subject of our continued investigation. In addition,
our study lacks baseline QOL data, thus precluding
a comparison of preoperative and postoperative QOL.
However, the Johns Hopkins NTOS patient population
examined in the study of short-term QOL outcomes by
Chang et al2 largely overlaps with the population examined
in our analysis. Chang et al reported a baseline mean PCS
of 33.8 and MCS of 44.5, which are lower (worse QOL)
than the mean postoperative PCS of 44.3 and MCS of
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2 Rochlin et al 44351.3 in our current study. We also plan to conduct
a prospective trial utilizing the QOL surveys used in this
study pre- and postoperatively, in which patients will be
randomized to surgery or Botox injections. Patients with
comorbid conditions might perform better with pain
management, physical therapy, and/or Botox compared
with surgery. Other limitations include the 53.7% response
rate and potential for nonresponse bias. However, the
noted differences in gender and proportion of bilateral
FRRS procedures between respondents and nonrespon-
dents likely did not have an impact on the outcomes of
our study because neither variable was signiﬁcantly predic-
tive of survey score on any instrument in our analysis.
CONCLUSIONS
The mean QOL scores reported in this study and the
absence of signiﬁcant difference in QOL with longer
follow-up support the use of transaxillary FRRS as an effec-
tive and durable treatment strategy for NTOS refractory
to conservative management. Clinical assessment can
adequately predict patient-reported QOL, although stan-
dardized measures are still needed to objectively measure
postoperative improvement. Pain and sensory disturbances
after FRRS are most often localized to the shoulder and
ﬁngers, respectively, with diffuse and uncommon patterns
of residual symptoms associated with greater impairment.
Finally, although a preoperative scalene block has diag-
nostic and short-term prognostic value, scalene block
outcome was not associated with QOL in our long-term
analysis. Patient factors, particularly comorbid conditions
and opioid use, have greater predictive value in the long
term and should be considered during evaluation of
surgical candidacy and formulation of postoperative treat-
ment plans.
AUTHOR CONTRIBUTIONS
Conception and design: DR, MG, KL, EG, NF, PC, JF
Analysis and interpretation: DR, MG, KL, EG, JF
Data collection: DR, KL, EG, NF, PC, JF
Writing the article: DR, JF
Critical revision of the article: DR, MG, KL, EG, NF, PC, JF
Final approval of the article: DR, MG, KL, EG, NF, PC, JF
Statistical analysis: MG
Obtained funding: DR, JF
Overall responsibility: JF
REFERENCES
1. Brooke BS, Freischlag JA. Contemporary management of thoracic
outlet syndrome. Curr Opin Cardiol 2010;25:535-40.
2. Chang DC, Rotellini-Coltvet LA, Mukherjee D, De Leon R,
Freischlag JA. Surgical intervention for thoracic outlet syndrome
improves patient’s quality of life. J Vasc Surg 2009;49:630-7.
3. Christo PJ, Christo DK, Carinci AJ, Freischlag JA. Single CT-guided
chemodenervation of the anterior scalene muscle with botulinum
toxin for neurogenic thoracic outlet syndrome. Pain Med 2010;11:
504-11.4. Komanetsky RM, Novak CB, Mackinnon SE, Russo MH,
Padberg AM. Somatosensory evoked potentials fail to diagnose
thoracic outlet syndrome. J Hand Surg 1996;21:662-6.
5. Brantigan CO, Roos DB. Diagnosing thoracic outlet syndrome. Hand
Clin 2004;20:27-36.
6. Landry GJ, Moneta GL, Taylor LM, Edwards JM, Porter JM. Long-
term functional outcome of neurogenic thoracic outlet syndrome in
surgically and conservatively treated patients. J Vasc Surg 2001;33:
312-9.
7. Bosma J, Van Engeland M, Leijdekkers V, Vahl A, Wisselink W. The
inﬂuence of choice of therapy on quality of life in patients with
neurogenic thoracic outlet syndrome. Br J Neurosurg 2010;24:532-6.
8. Altobelli GG, Kudo T, Haas BT, Chandra FA, Moy JL, Ahn SS.
Thoracic outlet syndrome: pattern of clinical success after operative
decompression. J Vasc Surg 2005;42:122-8.
9. Degeorges R, Reynaud C, Becquemin JP. Thoracic outlet syndrome
surgery: long-term functional results. Ann Vasc Surg 2004;18:558-65.
10. Sharp WJ, Nowak LR, Zamani T, Kresowik TF, Hoballah JJ,
Ballinger BA, et al. Long-term follow-up and patient satisfaction after
surgery for thoracic outlet syndrome. Ann Vasc Surg 2001;15:32-6.
11. Axelrod DA, Proctor MC, Geisser ME, Roth RS, Greenﬁeld LJ.
Outcomes after surgery for thoracic outlet syndrome. J Vasc Surg
2001;33:1220-5.
12. Scali S, Stone D, Bjerke A, Chang C, Rzucidlo E, Goodney P, et al.
Long-term functional results for the surgical management of neuro-
genic thoracic outlet syndrome. Vasc Endovasc Surg 2010;44:550-5.
13. Rochlin DH, Likes K, Gilson MM, Christo PJ, Freischlag JA.
Management of unresolved, recurrent, and/or contralateral neurogenic
symptoms in patients following ﬁrst rib resection and scalenectomy.
J Vasc Surg 2012;56:1061-8.
14. Ware JE Jr, Kosinski M, Keller SD. A 12-item short-form health survey:
construction of scales and preliminary tests of reliability and validity.
Med Care 1996;34:220-33.
15. Cleeland CS. Measurement of pain by subjective report. In:
Chapman CR, Loeser JD, editors. Advances in pain research and
therapy. Volume 12: issues in pain measurement. New York: Raven
Press; 1989. p. 91-403.
16. Jordan SE, Ahn SS, Gelabert HA. Differentiation of thoracic outlet
syndrome from treatment-resistant cervical brachial pain syndromes:
development and utilization of a questionnaire, clinical examination
and ultrasound evaluation. Pain Physician 2007;10:441-52.
17. Cordobes-Gual J, Lozano-Vilardell P, Torreguitart-Mirada N, Lara-
Hernandez R, Riera-Vazquez R, Julia-Montoya J. Prospective study of
the functional recovery after surgery for thoracic outlet syndrome. Eur
J Vasc Endovasc Surg 2008;35:79-83.
18. Green RM, McNamara J, Ouriel K. Long-term follow-up after thoracic
outlet decompression: an analysis of factors determining outcome.
J Vasc Surg 1991;14:739-46.
19. Bhattacharya V, Hansrani M, Wyatt M, Lambert D, Jones N. Outcome
following surgery for thoracic outlet syndrome. Eur J Vasc Endovasc
Surg 2003;26:170-5.
20. Hameed SM, Grewal RP, Urschel JD. Somatization tendencies in
surgically treated neurogenic thoracic outlet syndrome patients. Vasc
Endovasc Surg 1995;29:185-8.
21. Torriani M, Gupta R, Donahue DM. Sonographically guided anes-
thetic injection of anterior scalene muscle for investigation of neuro-
genic thoracic outlet syndrome. Skeletal Radiol 2009;38:1083-7.
22. Lum YW, Brooke BS, Likes K, Modi M, Grunebach H, Christo PJ,
et al. Impact of anterior scalene lidocaine blocks on predicting surgical
success in older patients with neurogenic thoracic outlet syndrome.
J Vasc Surg 2012;55:1370-5.
23. Jordan SE, Machleder HI. Diagnosis of thoracic outlet syndrome using
electrophysiologically guided anterior scalene blocks. Ann Vasc Surg
1998;12:260-4.Submitted Jun 7, 2012; accepted Aug 22, 2012.
